CompletedNCT06202599

Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance

Studying Bone sarcoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Peking University People's Hospital
Principal Investigator
Lu Xie, M.D., MD
Musculoskeletal Tumor Center of Peking University People's Hospital
Intervention
Fruquintinib(drug)
Enrollment
124 enrolled
Eligibility
All sexes
Timeline
20212023

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06202599 on ClinicalTrials.gov

Other trials for Bone sarcoma

Additional recruiting or active studies for the same condition.

See all trials for Bone sarcoma

← Back to all trials